[Correspondence] Clinical implications and biomarkers in the PACT-21 CASSANDRA trial
We read with great interest the initial report on the PACT-21 CASSANDRA study by Michele Reni and colleagues.1 We argue that although the event-free survival benefit of PAXG (cisplatin, nab-paclitaxel, capecitabine, and gemcitabine) over mFOLFIRINOX (modified fluorouracil, leucovorin, irinotecan, an
ORIGINAL SOURCE →via The Lancet
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · conflict
- [CONFLICT] Intermodal Asia
- [CONFLICT] [World Report] Health on the ballot in Senedd Cymru election
- [CONFLICT] [Perspectives] Amita Aggarwal: understanding autoimmune rheumatic diseases
- [CONFLICT] [Perspectives] Of memory, love, death, and Proust
- [CONFLICT] [Perspectives] Myopic medical harm: a man receives free colon cancer screening in Ghana
- [CONFLICT] [Correspondence] Ultra-processed food policy must regulate the screen as well as the street